Kornimate/medical-research-clean huggingface dataset:
surgical treatment for morbid obesity by sleeve gastrectomy versus gastric bypass

Conditions: Obesity

Summary: the aim of this study is to assess that the sleeve gastrectomy can improve the risk benefit than the gastric bypass

in the obese patient population, the frequency of patients presenting a severe morbid obesity (40 \>= bmi \ 50), a super super obesity (bmi\>60), and obese patients (bmi\>35) with a failure of gastric banding is constantly increasing. in these patients, the surgery risk is proportionate to the weight and / or gastric surgery records. this risk is high, in bariatric surgery, for gastric bypass procedure. this justifies the evaluation of new procedure to reduce the morbidity allowing the reduction of morbid /mortality associated with the intervention.

Eligibility criteria:
inclusion criteria: * patient aged from 18 to 60 years old * patient having given his consent to the use of data from the project * patient fulfilling the inclusion criteria for surgery of obesity according to the anaes (french national health service) * patient presenting one of the following criteria: * a morbid obesity strict with bmi\> 40 * a super obesity bmi\> 50 * a super super obesity bmi\> 60 * obese patient in failure following the installation of a gastric banding with bmi\> 35 * obese patient 35\>bmi\>40 with a comorbidity * preliminary agreement during the consultation of a psychiatrist / psychologist exclusion criteria: * patient with complications or co morbidities associated involving life to less 6 months * patient presenting no anaesthetic indication * patient presenting no psychiatric indication for obesity surgery * patient not affiliated with a social security scheme * pregnant patient likely to breastfeed in the first year

Keywords: morbid obesity sleeve gastrectomy gastric bypass complications efficacity safety compare
effect of growth hormone on bone metabolism in anorexia nervosa

Conditions: Anorexia Nervosa; Osteopenia; Osteoporosis; Eating Disorders

Summary: decreased bone strength is a serious medical problem present in many women with anorexia nervosa, or disordered eating. women with weaker bones are more likely to suffer broken bones than women with normal bone strength. we are investigating whether a hormone that is naturally produced by the human body, called growth hormone, can help strengthen the bones of women with this type of disordered eating.

* twelve week study * eight visits, six of which can be conducted at your home physician's office * two bone density scans * hormonal and nutritional evaluations

Eligibility criteria:
inclusion criteria: * women between 14 to 45 years with anorexia nervosa exclusion criteria: * pregnancy * previous history of malignancy. * oral contraceptive pills or other hormones within last 8 - 12 weeks * medications known to affect bone within last 12 weeks * fracture within last 6 months

Keywords: anorexia nervosa eating disorder bone growth hormone osteopenia osteoporosis
single dose study of mk-2060 to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics in older japanese participants on dialysis (mk-2060-012)

Conditions: End-Stage Renal Disease (ESRD); End-Stage Kidney Disease (ESKD); Kidney Failure, Chronic

Summary: the purpose of this study is to assess the safety, tolerability, pharmacokinetics (pk) and pharmacodynamics (pd) of mk-2060 after a single dose intravenous (iv) administration in japanese older participants with end stage renal disease (esrd) on dialysis. there is no primary hypothesis for this study.


Eligibility criteria:
inclusion criteria: the main inclusion criteria include but are not limited to the following: * japanese descent with all 2 biological parents of japanese descent * on hemodialysis (hd) or hemodiafiltration (hdf) with single-pool kt/v (spkt/v) ≥1.2, using arteriovenous (av) fistula or av graft ≥3 months prior to screening 1 at a healthcare center, and is on the same dialysis regimen ≥2 weeks prior to screening 1 * be judged to plan to continue or anticipate the use of the current av fistula or av graft until the poststudy visit exclusion criteria: the main exclusion criteria include but are not limited to the following: * on peritoneal dialysis or other dialysis modalities except for hd and hdf * history of deep vein thrombosis or pulmonary embolism * history of vascular access thrombosis within 1 month prior to screening 1 * personal or family history of bleeding disorder * history of gi bleeding, duodenal polyps or active gastroduodenal ulcer within 5 years prior to screening 1, or history of severe hemorrhoidal bleed within 3 months prior to screening 1 * history of frequent epistaxis within 3 months prior to screening 1 or active gingivitis * at the time of screening or predose, planned significant dental procedures, or other planned surgical procedures within duration of participation in the trial * history of receiving any human immunoglobulin preparation such as intravenous immunoglobulin (ivig) or a brand of rho(d) immune globulin (rhogam) within 1 year prior to screening 1 * history of receiving any biological therapy within 3 months prior to screening 1, or vaccination within 1 month prior to the dose of study intervention * requires or anticipates requiring the use of following prohibited medications until the poststudy visit: anticoagulants, antiplatelet medications and non-steroidal anti-inflammatory drugs (nsaids) * participated in another investigational study within 1 month prior to screening 1 * has blood coagulation test (activated partial thromboplastin time \[aptt\] or prothrombin time \[pt\]) above 1.2x upper limit of normal (uln) at screening 1 from the central laboratory for safety
assess fibrin in brains with ad/adrd

Conditions: Alzheimer Disease; Dementia of Alzheimer Type

Summary: the goal of this project is to quantify brain fibrin content using 64cu-fbp8-pet in the brains of subjects ranging from cognitively normal to clinically diagnosed with adrd to evaluate potential regional differences.

while there are many potential therapeutics being evaluated for alzheimer's disease and related dementias (adrd), there is currently no known cure for adrd and its origin and pathophysiology are still not well understood. however, the association of fibrin with adrd is becoming increasingly clearer. up to now it was not possible to quantify brain fibrin in vivo to better elucidate its role in adrd, but recently, 64cu-fbp8 was proposed as a tool to detect thrombus anywhere in the body. this unique tool will allow us to non-invasively assess brain fibrin levels in at-risk and adrd subjects. the goal of this project is to use 64cu-fbp8-pet in the brains of subjects ranging from cognitively normal to clinically diagnosed with adrd to assess fibrin levels. it is expected that about 30 people will take part in this research study. 64cu-fbp8-pet is not currently approved by the u.s. food and drug administration (fda).

Eligibility criteria:
inclusion criteria: * age between 55 and 90 years * ability to provide informed consent * specific to healthy volunteers: no history of adrd * specific to adrd subjects: clinical diagnosis of ad - either amnestic or atypical, clinical severity ranging from mci to moderate dementia (cdr 0.5-2.0), mmse score greater than or equal to 15 and/or moca greater than or equal to 12 * specific to band subjects: referred through the brain aging and dementia (band) research registry exclusion criteria: * mr contraindications such as: electrical implants such as cardiac pacemakers or perfusion pumps; ferromagnetic implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, valves with steel parts, metal fragments, shrapnel, tattoos near the eye, or steel implants, ferromagnetic objects such as jewelry or metal clips in clothing * preexisting medical conditions including a likelihood of developing seizures or claustrophobic reactions, and any greater than normal potential for cardiac arrest * subjects whose estimated glomerular filtration rate (egfr) \< 60 ml/min will be excluded from receiving the gadolinium-based contrast agent * research-related radiation exposure exceeding current massachusetts general hospital (mgh) radiology department guidelines (i.e. 50 millisievert in the prior 12 months) * 3. in line with published mgh irb guidelines for pregnancy must be ruled out by urine ß-hcg if answers to screening questions suggest that pregnancy is possible and if female participants are premenopausal and of child-bearing age. subjects will not be able to enroll if they are breastfeeding.

Keywords: alzheimer disease dementia
sleep quality, heart rate variability and anxiety following brain injury

Conditions: Traumatic Brain Injury; Anxiety

Summary: the investigators predict that decreased heart rate variability and poor sleep quality will be significantly correlated with higher self-reported anxiety following brain injury.

acute rehabilitation inpatients with moderate-to-severe brain injury will wear biosensors that track total sleep time and heart-rate variability for up to 1 week. during this time the participants will also complete surveys regarding symptoms of anxiety. the investigators hypothesize that decreased heart rate variability and poor sleep quality will be significantly correlated with higher self-reported anxiety following brain injury.

Eligibility criteria:
inclusion criteria: * traumatic brain injury * injury within past 6 months * medically stable * able to communicate exclusion criteria: * on medication: beta-blocker * adverse skin reaction to biosensor adhesive * non-english speaking * pregnant women * prisoners

Keywords: heart rate variability sleep
study of management of appendicular abscess

Conditions: Appendiceal Abscess

Summary: this study aims to detect indications of surgical drainage after failure ultrasound guided percutaneous drainage this study will include any male and female above 18 years old that presented with appendicular abscess patients with appendicular abscess above the age of 18 years old all patients with generalized peritonitis or immunocompromised patients will be excluded from the study

prospective randomized study we will collect 30 patients diagnosed with appendicular abscess and they all will undergo ultrasound guided percutaneous drainage of abscess and the group who will fail to insert the pigtail will undergo surgical drainage we will record the time of operation, number of cases with intraoperative complications and then follow up these patients during time of hospital stay for post operative pain and paralytic ileus study outcomes: primary outcomes: 1. incidence of intra operative complications 2. length of operations 3. post operative pain 4. incidence of intraoperative complications as injury of important structures 5. lenght of hospital stay 6. incidence of post operative complications related to surgery as wound infection, recurrence, intestinal obstruction secondary outcomes: 1. cosmotic outcomes 2. incidence of recurrence of pathology 3. patient satisfaction

Eligibility criteria:
inclusion criteria: * patients with appendicular abscess above the age of 18 years old exclusion criteria: * generalized peritonitis and patients with signs of spreading infection, toxemia and septicemia multi-locular appendicular abscess immunocompromised patients, hepatic dysfunction, renal impairment, uncontrolled patients and cardiac disease
exercise training intensity and nitrate supplementation in post-menopausal females

Conditions: Menopause

Summary: menopause greatly increases cardiovascular disease risk (cvd). current exercise guidelines are inadequate to ameliorate this risk and higher intensity exercise may be necessary for cardiovascular benefits in postmenopausal females. oral nitrate supplementation enhances exercise performance and cvd risk profile in several clinical conditions. the investigators recently reported that 3-days of nitrate supplementation in postmenopausal females enhances acute post-exercise vascular function, in an intensity dependent manner. the effects of nitrate supplementation and exercise training over a longer training program remains unexplored. this investigation will examine the impact of exercise training intensity with and without inorganic nitrate supplementation, on cvd and fitness outcomes. postmenopausal females will be tested for maximal oxygen uptake and lactate threshold before randomization to one of four groups: that inorganic nitrate-rich tablets, or tablets with nitrate extracted; and assigned to one-month of calorie matched high-intensity or moderate-intensity exercise training. vascular function and fitness will be evaluated before and after training.


Eligibility criteria:
inclusion criteria: * post-menopausal female (greater than age 45 but less than age 75) * sedentary (does not exercise regularly or less than 2 bouts of exercise per week) * no major changes in medication in the last 3 months exclusion criteria: * smokers within last 5 years * weight unstable (loss/gain of more than 3kg in the past 3 months) * any medical condition that prevents the subject from exercising safely * hormone replacement therapy (current or within last 3 months) * diabetes * currently or recently on vasoactive medications (i.e., calcium channel blockers, statins, ace or renin inhibitors, arbs, nitrates, alpha- or beta-blockers, diuretics, proton pump inhibitors, etc.) * oral antibiotic use within previous four weeks * oral disease or poor oral health as determined by the oral health questionnaire * using an antibacterial mouthwash or a mouthwash containing chlorhexidine and unwilling to discontinue use

Keywords: inorganic nitrate menopause high intensity exercise vascular health
prognosis in neurological intensive care unit patients (pronicu cohort)

Conditions: Neurological Diseases

Summary: this study examines the prognostic properties of immune parameters, clinical scores, electrophysiological tests (eeg, ssep, emg, eng) and functional imaging for the prediction of functional outcome one year after treatment on a neurological intensive care unit.


Eligibility criteria:
inclusion criteria: * severe neurological disease making treatment on a neurological intensive care unit necessary * age ≥ 18 * consent by the patient or the legal representative exclusion criteria: * participation in an interventional trial

Keywords: severe neurological diseases neurological intensive care unit prediction long-term outcome biomarkers prediction of long-term outcome
positively smoke free on the web (psfw) for smokers living with hiv

Conditions: Tobacco Use Cessation; Tobacco Cessation; Tobacco Use Disorder; Tobacco Dependence; Tobacco-Use Disorder; Virus, Human Immunodeficiency

Summary: the purpose of this study is to evaluate the first web-based cessation program developed expressly for people living with hiv who smoke tobacco. main study goals are (1) to evaluate the website's feasibility (i.e., recruitment, adherence, retention, and satisfaction) and (2) to complete a prospective, randomized controlled trial comparing the efficacy of the online program to standard care with a primary outcome of 3 month point-prevalence abstinence.

positively smoke free on the web is the first web-based cessation program developed expressly for people living with hiv (plwh) who smoke tobacco. it is a resource that is ready for clinical use, but its feasibility and efficacy have yet to be studied. main study goals are (1) to evaluate the website's feasibility (i.e., recruitment, adherence, retention, and satisfaction) in a cohort of 69 plwh smokers, and (2) to complete a prospective, randomized controlled trial comparing the efficacy of the online program to standard care (total n = 138) with a primary outcome of 3 month point-prevalence abstinence.

Eligibility criteria:
inclusion criteria: * laboratory confirmation of hiv infection * montefiore medical center infectious disease clinic patient * current tobacco user * affirmed motivation to quit within the next 6 months * have home access to the internet * read above 4th grade level (by realm) * willingness to grant informed consent and undergo randomization exclusion criteria: * pregnant or breastfeeding women * people with contraindications to nicotine replacement therapy * people currently receiving other tobacco treatment * spouses, partners, and/or roommates of current study participants

Keywords: tobacco use cessation tobacco cessation tobacco use disorder tobacco dependence tobacco-use disorder virus, human immunodeficiency
resuscitation and capillary reperfusion

Conditions: Cardiac Arrest; Cardiac Arrest, Out-Of-Hospital; Cardiopulmonary Arrest; Cardiopulmonary Arrest With Successful Resuscitation

Summary: persistent microperfusion alterations after return of spontaneous circulation (rosc) are associated with poor survival. to our knowledge, no human studies evaluating microperfusion during cardiopulmonary resuscitation (cpr) with simple and pre-hospital available tests have been published. capillary refill time (crt) and skin-mottling-score (sms) are parameters for microperfusion and evaluated in septic and cardiogenic shock. in animal studies, microperfusion was impaired during cardiac arrest, although not correlating with systemic blood pressure. the aim of this study is to investigate the correlation between impaired microcirculation (as measured with crt and sms) during resuscitation and rosc resp. neurological outcome. our clinical impression in daily routine is, that the appearance of a patient undergoing cpr is often linked to the outcome. we hypothesize, that this is due to changes in microperfusion of the skin.


Eligibility criteria:
inclusion criteria: * all patients ≥18 years during cardiopulmonary resuscitation * witnessed cardiac arrest exclusion criteria: * insufficient manpower (e.g. study team has to provide cpr) * hypovolemia (exsanguination, anaphylaxis, sepsis as underlying cause) * presumed or known covid-19 disease * hypo-/hyperthermia (\ 37.5°c) * raynaud's disease * peripheral arterial disease

Keywords: capillary refill time skin mottling score capillary lactate microperfusion cardiopulmonary resuscitation
cancer sensing: evaluation of odour sampling techniques

Conditions: Skin Cancer

Summary: to evaluate the suitability of two odour capturing techniques for early detection of skin cancer.

the study will investigate the suitability of two odour capturing techniques for early detection of skin cancer. the techniques to capture vocs are: a) solid phase microextraction (spme) and b) collection of vocs via an adsorptive patch, worn on the skin. the objective is to evaluate the suitability of two techniques for collecting vocs. odour samples from cancerous and healthy skin will be captured using the two non-invasive techniques. the techniques will initially be tested in a laboratory environment. they will then be applied in parallel to patients and healthy people. voc compounds of odour samples will be analysed for their profiles in respect of cancerous and healthy skins. the vocs profiles will be recorded in a voc bank for future analysis. following the initial tests, patients (n=20) with skin cancer will be recruited from poole and dorset county hospitals. arrangement will be made to obtain odour samples by positioning patches on the cancerous skin sites (for approximately 30 minutes) of patients and recover them. to obtain samples from healthy people (n=10), staff and students within the university are invited to participate in this research by providing odour samples from their skins using the same type of patches. in parallel, vocs from skin cancer patients will also be collected from patients with the spme fibres described earlier. the spme device is roughly equivalent in size and shape to a ballpoint pen, from the tip of which an adsorbent fibre can be extended. the spme device is held statically with a flexible clamp (a weighted clamp which rests on a bench / desk near the patient), and is positioned so that the tip of the fibre rests close to, but not touching, the affected skin area. the fibre needs to be held in place to sample the air above the affected skin for a pre-determined period of time, likely to be 15 - 30 minutes. specifics such as the sampling time and related factors will be evaluated during the initial laboratory testing. following the defined time period of sampling, the fibre is retracted into the body of the spme device (to protect it), and the device is returned to the laboratory for analysis. the high temperatures involved in gcms analysis cause vocs captured by the spme device to be released (desorbed) and they are subsequently swept through the gcms system for analysis. the voc samples from both the techniques will be transported to bournemouth university for analysis. the outcome will be the identification of the most suitable voc collection technique (spme vs patch) by comparing the voc profiles of cancerous and healthy skin.

Eligibility criteria:
inclusion criteria: * patients diagnosed with skin cancer, able to speak and understand written english, * 18 years or older and * capable of giving informed consent. exclusion criteria: * patients too weak to speak or give written informed consent; * non-english speaking without an interpreter; * patients lacking mental capacity to consent, or * below the age of 18.
clinical and sonographic diaphragm evaluation post-plication

Conditions: Diaphragmatic Plication; Unilateral Diaphragmatic Paralysis; Diaphragm Ultrasonography

Summary: objectives: we aim to clarify the role of diaphragm ultrasonography (dus) in evaluating the outcome of surgical diaphragmatic plication (sdp) in adults with symptomatic unilateral diaphragmatic paralysis (udp).


Eligibility criteria:
inclusion criteria: - symptomatic unilateral diaphragmatic paralysis. exclusion criteria: * children * morbid obesity * certain neuromuscular disorders * previous thoracic surgical intervention on the affected * recurrent eventration

Keywords: diaphragmatic eventration diaphragm dyspnea
two schemes response in multiple myeloma

Conditions: Response, Acute Phase; Survivorship

Summary: retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the vtd or td combination.

the most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators, proteasome inhibitors, etc. the vtd (bortezomib, thalidomide, and dexamethasone) and td (thalidomide and dexamethasone) regimens are commonly used as a first-line treatment due to limited resources. the study aimed to compare the proportion of favorable responses, survival, and time to the next treatment between two different treatment approaches. the investigators designed a retrospective study based on medical records of patients with multiple myeloma, eligible for stem cell transplantation, who received, first-line, the vtd or td combination.

Eligibility criteria:
inclusion criteria: * clinical records of patients who were considered eligible for transplant due to their functional status and who were given some treatment strategy comprising a combination of drugs. exclusion criteria: * incomplete clinical records * clinical records of patients who abandoned treatment or could not continue with the treatment due to economic or distance issues * clinical records of patients who presented severe sepsis before the beginning of either treatment

Keywords: multiple myeloma bortezomib thalidomide acute phase response survival